… In this randomised, double-blind, phase 2 dose-finding study, we compared asundexian
20 mg or 50 mg once daily with apixaban 5 mg twice daily in patients aged 45 years or older …

… Oral factor Xa inhibitors (FXaI) can be administered in fixed doses without the need for …
levels may be useful in guiding decisions for reversal of anticoagulation in emergent settings, …

… role of anti-Xa levels in managing patients with an emergent … of rivaroxaban and apixaban
before emergent procedures or … apixaban and rivaroxaban reversal utilizes factor 8 inhibitor …

… oral factor Xa inhibitors. We evaluated the operational processes and outcomes of patients
with oral factor Xa inhibitor‐… The incidence of new thrombosis within 30 days of antithrombotic …

… However, we found that the validated STA-Liquid Anti-Xa assay using calibrator kits for
apixaban and rivaroxaban and LC–MS/MS data for edoxaban had similar calibration lines for the …

… the new DOACs, including apixaban, they are rare and are usually associated with vasculitis.
To the best of our knowledge, apixaban-… can be associated with apixaban and that with the …

… of Factor Xa inhibitors (FXaIs), currently four drugs: rivaroxaban (Xarelto), apixaban (Eliquis), …
In patients who had received apixaban, the median anti-factor Xa activity decreased from …

… new agents, this paper (a) describes the unmet needs in oral anticoagulation therapy, (b)
explains why FXI is a promising target for new oral … For example, rivaroxaban and apixaban …

… modified recombinant inactive form of human factor Xa that was designed specifically to bind
and sequester factor Xa inhibitor molecules thereby rapidly reducing anti-factor Xa activity. …

… New agents like enoxaparin, apixaban and rivaroxaban is use for the treatments of Venous
… class of clotting factor Xa inhibitor. Betrixaban became first anticoagulant(by inhibit factor Xa) …